• 08 Sep 21

Tissue Regenix delivers first-half results that show a strong recovery as it builds its portfolio

Tissue Regenix delivers first-half results that show a strong recovery as it builds its portfolio

Tissue Regenix Group plc | TRX | 30.5 0 0%

    • 134 views

 

Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF) CEO Danny Lee and CFO David Cocke joined Proactive's Stephen Gunnion with details of the company's interim results, which show a strong recovery following the coronavirus (COVID-19) pandemic with revenues up 21% in constant currency.

Lee telling Proactive that Tissue also successfully completed Phase 1 of its facility expansion in the period and successfully completed development of two additional products to its portfolio.

Enjoying this article?

Get a £25 credit by sharing with your friends and colleagues via our Refer a Friend page. Each new subscriber gets a 10% discount and you get a free month off your bill every time.


Don't worry, if you're a Lite-Access/Free user we save all your credits for the day you decide to fully subscribe.


 

Tissue Regenix unveils growth strategy and positive EBITDA milestone

Companies: Tissue Regenix Group plc

Executive Interview - Tissue Regenix

Companies: Tissue Regenix Group plc

Tissue Regenix Group says "disciplined approach" paying off at half-year stage

Companies: Tissue Regenix Group plc

Tissue Regenix present full year trading update, hailing a 13% increase in total revenues

Companies: Tissue Regenix Group plc

Tissue Regenix Group 'has evolved from an R&D organisation to now focus on commercialisation'

Companies: Tissue Regenix Group plc

Tissue Regenix Group says 'maintaining level of sales is true testament to demand of our products'

Companies: Tissue Regenix Group plc

© Research Tree 2025

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top